Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine for Post-laryngectomy Depression (HADS, fMRI, Inflammatory Markers)
ChiCTR2500109357Phase 4Not yet recruiting
- Sponsor
- Shandong Second People's Hospital
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of esketamine in major depressive disorder (MDD) (2 arms), sponsored by Shandong Second People's Hospital. Primary endpoint: Hospital Anxiety and Depression Scale (HADS). Planned start Sep 2025; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2500109357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109357.